Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured,
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... as XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present at the following upcoming investor ... & Renshaw 16 th Annual Global Investment ... September 9, 2014 at 9:10 a.m. EDT , ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 /PRNewswire/ ... an oncology company focused on the clinical development ... it has completed enrollment in a randomized Phase ... candidate Pracinostat in combination with azacitidine in patients ... (MDS). The multi-center, placebo-controlled, double-blind study enrolled a ...
(Date:9/2/2014)... ANTONIO , Sept. 2, 2014 ... medical technology company focused on innovating lifesaving devices ... the appointment of Dr. Gabriele Niederauer , ... and CEO. Following the recent closure of Series ... Mark for the Surfacer™ Inside-Out Access Catheter System, ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2
... THOUSAND OAKS, Calif., Sept. 24 Amgen (Nasdaq: ... EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily ... as a precaution.  The product that is being recalled ... barely visible in most cases. The lamellae result from ...
... Pharmasset, Inc. (Nasdaq: VRUS ) announces that management ... September 27-28, 2010 at the New York Palace Hotel, New ... will provide an overview of the company at the JMP ... To access a simultaneous webcast of Mr. Price,s ...
Cached Medicine Technology:Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 2Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 3Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 4Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 5Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 6Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 7Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 8Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 9Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 10Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 11Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 12Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 13Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 14Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 15Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 16Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 17Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 18Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 19Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 20Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 21Pharmasset to Present at the JMP Healthcare Conference 2Pharmasset to Present at the JMP Healthcare Conference 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 - Molecular ... as a class of diagnostic test that analyzes proteins ... nucleic acids and proteins that belong to individual patients ... health condition, or risk of developing a specific disease. ... known as (MDx) evaluating the new class of diagnostic ...
(Date:9/2/2014)... A little white pill may help scientists learn ... than their peers, even if their lungs are relatively ... marketed as Revatio to treat pulmonary hypertension and ... cocktail of over-the-counter antioxidants will help them identify the ... difficult for these patients. , "We want to ...
(Date:9/2/2014)... The Society of Nuclear Medicine and Molecular Imaging (SNMMI) ... SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 ... the late Kanji Torizuka, MD, PhD, is designed to ... nuclear medicine and molecular imaging for Japanese physicians in ... "SNMMI is proud to sponsor the Wagner-Torizuka Fellowship. This ...
(Date:9/2/2014)... 2014 Vertebral invasive compression fractures called ... vertebrae in our spine suffers crack or gets deformed. ... in people with osteoporosis or low bone density. Though ... forms of metastatic tumors and extensive trauma such as ... can also lead to such fractures. , The placement ...
(Date:9/2/2014)... 02, 2014 Concorde Career College ... to receive the 2014 Excellence in Community Service ... and Colleges (ACCSC). , Every year, the Accrediting ... members who make outstanding contributions in their local ... for the scope and impact of the community ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 3Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- ... lost? Seeking out the right Web site might help, a ... logged on to a specially designed Internet site for weight maintenance ... loss than people who logged on less often, new research finds. ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) -- An ... to help severely disabled people play computer games, express themselves ... experimental "sniff controller" takes advantage of the fact that cranial ... still able to send messages to the soft palate (the ...
... (BRONX, NY) For the third time in four months, ... the National Institutes of Health (NIH) has awarded Albert Einstein ... at helping people infected with multidrug-resistant tuberculosis (MDR-TB). ... The latest awardee Neel Gandhi, M.D. , assistant ...
... that patients often exhibit a significant decrease in weight and body ... The study is the first of its type to correct ... between the ages of 29 to 73 years. The study ... of 196 Mount Sinai patients who had knee or hip replacement ...
... What,s a baseball game or a football game or a ... offer a staggering array of food from appetizers to desserts. But ... beer. A special news media briefing and reception will focus ... 240th National Meeting & Exposition , which be held here ...
... 2010) A major research company affiliated with the ... is partnering with the University of Colorado,s Anschutz Medical ... discoveries from the laboratory to the patient. CPC, formally ... the University Physicians Incorporated building across the street from ...
Cached Medicine News:Health News:To Help Keep Weight Off, Turn to the Web 2Health News:To Help Keep Weight Off, Turn to the Web 3Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 2Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 3Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Many knee and hip replacement patients experience weight decrease after surgery 2Health News:Special news media briefing and reception during American Chemical Society national meeting 2Health News:University of Colorado joins forces with major research affiliate 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: